良性前列腺增生治療器材市場－全球產業規模、佔有率、趨勢、機會及預測（依治療方法、手術、產品、最終用途、地區及競爭格局分類），2021-2031年

全球良性前列腺增生治療器材市場預計將從2025年的130.6億美元成長至2031年的172.1億美元，複合年成長率（CAGR）為4.71%。該市場涵蓋多種微創和外科手術技術，例如雷射消熔系統、電外科器械和前列腺尿道提升植入，所有這些技術都旨在緩解非惡性前列腺增生引起的下泌尿道症狀。推動市場成長的關鍵因素是男性人口的快速老化以及臨床上對微創療法（相比傳統手術恢復時間更短）的強烈偏好，這確保了市場需求的持續穩定，不受暫時趨勢的影響。

然而，該市場面臨著許多障礙，例如針對新型醫療設備技術的複雜報銷體系，這往往限制了預算緊張的醫療保健系統中患者獲得和使用此類技術的機會。美國泌尿系統協會的報告凸顯了這個問題的嚴重性：到2024年，65歲及以上男性良性前列腺增生的盛行率將達到29%至35%。如此高的盛行率凸顯了該領域對便捷治療方案日益成長的需求和重要性。

市場促進因素

機器人輔助系統和雷射消熔技術的創新正在改變市場格局，其重點在於提高手術精準度和加快術後恢復速度。這些進步正迅速取代傳統的經尿道切除術，臨床醫生和患者都越來越傾向於選擇自動化、組織保留性手術技術，以減少性功能障礙和住院時間。新興市場領導的財務成功也反映了這一轉變；例如，PROCEPT BioRobotics公司公佈的2024年第三季財報顯示，其營收年增66%，達到5,840萬美元，這主要得益於其Aquablation機器人系統的強勁應用。

此外，由於老化與攝護腺增生密切相關，全球老年人口的成長是推動市場長期成長的關鍵人口因素。隨著預期壽命的延長，越來越多的男性出現下泌尿道症狀，催生了對可擴展醫療解決方案的需求。根據聯合國人口基金會發布的《2024年世界人口展望》，到2024年，65歲及以上人口將佔世界人口的10.3%，顯示患者群體結構發生了顯著變化。這一人口趨勢正在創造商業性機遇，波士頓科學公司2025年2月發布的報告也證實，其泌尿系統部門在2024會計年度的全年淨銷售額將成長12.0%，進一步印證了老年人口日益成長的需求。

市場挑戰

全球良性前列腺增生治療器材市場的成長受到創新技術複雜報銷環境的顯著阻礙，這對醫療機構造成了財務障礙。新器材經常在缺乏既定計費代碼或有利的保險覆蓋範圍的情況下上市，迫使醫療機構自行承擔成本或適應難以預測的付款模式。這種財務上的不確定性阻礙了醫院和泌尿系統診所購買昂貴的器械，導致他們優先選擇已建立且可全額報銷的成熟療法，而不是更新、可能更有益的治療方案。

因此，泌尿系統的利潤空間正在縮小，進一步限制了新興治療方法的應用範圍。根據美國泌尿系統協會 (AUA) 2024 年的報告，美國醫療保險和醫療補助服務中心 (CMS) 最終確定了支付規則，將在下一財政年度將醫療保險轉換係數降低約 2.83%。報銷率的降低嚴重加重了醫療服務提供者的經濟負擔，直接限制了他們採用新型設備治療良性前列腺增生 (BPH) 的能力，並在注重成本的醫療環境中抑制了整體市場成長。

市場趨勢

臨時性鎳鈦合金植入裝置的引入標誌著前列腺尿道非永久性機械再形成治療方式的重要轉變，使其區別於永久性支架和消融療法。諸如iTind系統之類的裝置旨在再形成膀胱頸，同時避免熱損傷和永久性植入，從而保留性功能，並解決患者對生活品質的重要關切。隨著製造商向關鍵地區擴張，這種創新方法正獲得商業性發展動力。例如，Olympus Corporation在2024年8月報告稱，2025會計年度第一季北美銷售額年增32%，這一業績部分歸功於iTind裝置的戰略市場部署。

同時，水蒸氣熱療的廣泛商業化應用，利用對流蒸氣能量有效治療增生，為門診手術樹立了新的標準。與機器人手術或雷射剜除術不同，該技術將無菌水蒸氣輸送至前列腺組織，迅速釋放熱能導致細胞死亡，無需大規模的手術設備。這項技術因其能在短時間內提供持久的症狀緩解而迅速普及，推動了主要醫療設備製造商的成長。波士頓科學公司於2024年10月發布的「2024會計年度第三季業績報告」顯示，泌尿系統淨銷售額成長10.3%，這主要得益於其前列腺健康業務（包括Rezum水蒸氣治療系統）的兩位數成長。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 良性攝護腺增生治療器材的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依治療方法（微創手術、侵入性手術）
  • 依手術方式（經經尿道前列腺切除術、攝護腺雷射手術、經尿道微波熱療、經尿道攝護腺針消融術、攝護腺尿道提升、水蒸氣治療、其他）
  • 依產品分類（電切鏡、泌尿系統雷射、射頻消融術、電極、導管、攝護腺支架、植入、其他）
  • 按用途（醫院/診所、研究/製造、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美良性攝護腺增生治療器材市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲良性前列腺增生治療設備市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章 亞太地區良性攝護腺增生治療設備市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲良性前列腺增生治療設備市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲良性攝護腺增生治療器材市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球良性前列腺增生治療設備市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Boston Scientific Corporation
• Olympus America
• Endo Pharmaceuticals Inc.
• biolitec AG
• Medifocus Inc.
• Cook Medical
• Teleflex Incorporated
• Urotronic
• Coloplast Corp
• Richard Wolf GmbH
• PROCEPT BioRobotics Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Benign Prostatic Hyperplasia Treatment Devices Market is projected to expand from USD 13.06 Billion in 2025 to USD 17.21 Billion by 2031, registering a CAGR of 4.71%. This market includes a variety of minimally invasive and surgical technologies, such as laser ablation systems, electrosurgical units, and prostatic urethral lift implants, all aiming to relieve lower urinary tract symptoms caused by non-malignant prostate enlargement. Growth is largely driven by a rapidly aging male population and a strong clinical preference for minimally invasive therapies that allow for faster recovery compared to traditional surgeries, ensuring lasting demand independent of fleeting trends.

However, the market faces a significant obstacle in the form of complex reimbursement structures for new device technologies, which often limit patient access and adoption within budget-conscious healthcare systems. Highlighting the magnitude of this issue, the American Urological Association reported in 2024 that the prevalence of Benign Prostatic Hyperplasia in men aged 65 and older ranged between 29% and 35%. This high prevalence reinforces the critical and increasing need for accessible therapeutic options within the sector.

Market Driver

Technological innovations in robotic-assisted systems and laser ablation are transforming the market by emphasizing precision and faster recovery times. These advancements are rapidly replacing traditional transurethral resections as both clinicians and patients favor automated, tissue-sparing methods that reduce sexual side effects and hospital stays. The financial success of emerging market leaders reflects this shift; for instance, PROCEPT BioRobotics reported a 66% year-over-year revenue increase to $58.4 million in its Third Quarter 2024 Financial Results, driven largely by the strong adoption of its Aquablation robotic systems.

Additionally, the growing global geriatric population serves as a major demographic driver for long-term market growth, due to the link between aging and prostate enlargement. As life expectancy rises, the number of men developing lower urinary tract symptoms increases, creating a need for scalable medical solutions. The United Nations Population Fund's '2024 State of World Population Report' noted that those aged 65 and older constituted 10.3% of the global population in 2024, indicating a major shift in patient density. This demographic trend creates commercial opportunities, as seen in Boston Scientific's February 2025 report, where the Urology segment saw a 12.0% rise in full-year 2024 net sales, confirming rising demand among the elderly.

Market Challenge

The growth of the Global Benign Prostatic Hyperplasia Treatment Devices Market is significantly hindered by a complicated reimbursement environment for innovative technologies, which creates financial hurdles for healthcare providers. New devices frequently launch without established billing codes or favorable insurance coverage, compelling medical facilities to either absorb the costs or navigate unpredictable payment models. This financial uncertainty deters hospitals and urology practices from purchasing expensive equipment, leading them to prefer established, fully reimbursed procedures over newer, potentially more beneficial alternatives.

As a result, urologists experience shrinking profit margins that further limit their capacity to incorporate emerging therapies. According to the American Urological Association in 2024, the Centers for Medicare & Medicaid Services finalized a payment rule reducing the Medicare conversion factor by approximately 2.83 percent for the following year. This cut in reimbursement rates intensifies financial strain on providers, directly restricting their ability to adopt novel BPH treatment devices and impeding overall market growth in cost-sensitive healthcare settings.

Market Trends

The introduction of temporary implantable nitinol devices marks a significant shift toward non-permanent, mechanical reshaping of the prostatic urethra, distinguishing these tools from permanent stents or ablative techniques. Devices such as the iTind system are engineered to remodel the bladder neck while preserving sexual function by avoiding thermal injury or permanent implants, thereby addressing a key quality-of-life concern for patients. This innovative method is gaining commercial momentum as manufacturers expand into key regions; for example, Olympus Corporation reported in August 2024 that its North American revenue rose by 32% year-over-year in the first quarter of fiscal year 2025, a result partly linked to the strategic market development of its iTind device.

Simultaneously, the broad commercialization of water vapor thermal therapy is setting a new benchmark for office-based procedures by using convective steam energy to treat hyperplasia effectively. Unlike robotic or laser enucleation, this modality delivers sterile water vapor into prostate tissue, rapidly dispersing thermal energy to cause cell death without requiring extensive surgical infrastructure. The technology's rapid adoption is driven by its ability to provide lasting symptom relief with short procedure times, contributing to growth for major device companies; Boston Scientific's 'Third Quarter 2024 Financial Results' in October 2024 showed a 10.3% increase in Urology net sales, bolstered by double-digit growth in its prostate health franchise, including the Rezum Water Vapor Therapy system.

Key Market Players

• Boston Scientific Corporation
• Olympus America
• Endo Pharmaceuticals Inc.
• biolitec AG
• Medifocus Inc.
• Cook Medical
• Teleflex Incorporated
• Urotronic
• Coloplast Corp
• Richard Wolf GmbH
• PROCEPT BioRobotics Corporation

Report Scope

In this report, the Global Benign Prostatic Hyperplasia Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Benign Prostatic Hyperplasia Treatment Devices Market, By Treatment

• Minimal Invasive Surgery
• Invasive Surgery

Benign Prostatic Hyperplasia Treatment Devices Market, By Procedure

• Transurethral Resection of the Prostate
• Prostate Laser Surgery
• Transurethral Microwave Thermotherapy
• Transurethral Needle Ablation of the Prostate
• Prostatic Urethral Lift
• Water Vapor Therapy
• Others

Benign Prostatic Hyperplasia Treatment Devices Market, By Product

• Resectoscopes
• Urology Laser
• Radiofrequency Ablation
• Electrodes
• Catheters
• Prostatic Stents
• Implants
• Others

Benign Prostatic Hyperplasia Treatment Devices Market, By End use

• Hospitals & Clinics
• Research and Manufacturing
• others

Benign Prostatic Hyperplasia Treatment Devices Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostatic Hyperplasia Treatment Devices Market.

Available Customizations:

Global Benign Prostatic Hyperplasia Treatment Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Minimal Invasive Surgery, Invasive Surgery)
  • 5.2.2. By Procedure (Transurethral Resection of the Prostate, Prostate Laser Surgery, Transurethral Microwave Thermotherapy, Transurethral Needle Ablation of the Prostate, Prostatic Urethral Lift, Water Vapor Therapy, Others)
  • 5.2.3. By Product (Resectoscopes, Urology Laser, Radiofrequency Ablation, Electrodes, Catheters, Prostatic Stents, Implants, Others)
  • 5.2.4. By End use (Hospitals & Clinics, Research and Manufacturing, others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Procedure
  • 6.2.3. By Product
  • 6.2.4. By End use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Procedure
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By End use
  • 6.3.2. Canada Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Procedure
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By End use
  • 6.3.3. Mexico Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Procedure
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By End use

7. Europe Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Procedure
  • 7.2.3. By Product
  • 7.2.4. By End use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Procedure
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By End use
  • 7.3.2. France Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Procedure
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By End use
  • 7.3.3. United Kingdom Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Procedure
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By End use
  • 7.3.4. Italy Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Procedure
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By End use
  • 7.3.5. Spain Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Procedure
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By End use

8. Asia Pacific Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Procedure
  • 8.2.3. By Product
  • 8.2.4. By End use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Procedure
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By End use
  • 8.3.2. India Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Procedure
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By End use
  • 8.3.3. Japan Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Procedure
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By End use
  • 8.3.4. South Korea Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Procedure
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By End use
  • 8.3.5. Australia Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Procedure
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By End use

9. Middle East & Africa Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Procedure
  • 9.2.3. By Product
  • 9.2.4. By End use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Procedure
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By End use
  • 9.3.2. UAE Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Procedure
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By End use
  • 9.3.3. South Africa Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Procedure
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By End use

10. South America Benign Prostatic Hyperplasia Treatment Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Procedure
  • 10.2.3. By Product
  • 10.2.4. By End use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Procedure
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By End use
  • 10.3.2. Colombia Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Procedure
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By End use
  • 10.3.3. Argentina Benign Prostatic Hyperplasia Treatment Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Procedure
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By End use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Benign Prostatic Hyperplasia Treatment Devices Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boston Scientific Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Olympus America
• 15.3. Endo Pharmaceuticals Inc.
• 15.4. biolitec AG
• 15.5. Medifocus Inc.
• 15.6. Cook Medical
• 15.7. Teleflex Incorporated
• 15.8. Urotronic
• 15.9. Coloplast Corp
• 15.10. Richard Wolf GmbH
• 15.11. PROCEPT BioRobotics Corporation

16. Strategic Recommendations

17. About Us & Disclaimer